Altamira Therapeutics to Present at Major Investment Conference
Hamilton, Bermuda — Altamira Therapeutics Ltd. (Nasdaq: CYTO), a leader in RNA delivery technology development, is gearing up to make an impact at the H.C. Wainwright 26th Annual Global Investment Conference. This event will be held both virtually and in person, offering participants the chance to engage in insightful discussions.
Key Details of the Event
The presentation is scheduled for September 9, 2024, at 7:00 AM ET. This event presents a valuable opportunity for Altamira's founder, Chairman, and CEO Thomas Meyer to showcase the company’s progress in RNA delivery that targets areas beyond the liver.
What to Expect
Participants will have the ability to access the presentation on-demand, which allows them to submit questions directly to the Company. This setup is designed to foster engagement, facilitate learning, and share insights regarding the exciting advancements in RNA delivery technology.
About Altamira Therapeutics and Its Innovations
Altamira Therapeutics is at the forefront of medical innovation with its unique peptide-based nanoparticle technologies that aim to enhance RNA delivery to tissues outside the liver. Two of its leading programs, AM-401 and AM-411, are focused on KRAS-driven cancers and rheumatoid arthritis, respectively, and are currently in the preclinical stage. This highlights the company’s dedication to developing therapies that address urgent medical needs.
Strategic Partnerships and Future Directions
Beyond its RNA delivery initiatives, Altamira holds a 49% interest in Altamira Medica AG, which includes its market-ready product Bentrio®, a nasal spray for allergic rhinitis. The company is actively pursuing new partnerships and considering potential divestments of its inner ear legacy assets, strategically positioning itself within the biotech industry.
Company Vision and Goals
Founded in 2003 and based in Hamilton, Bermuda, with significant operations in Basel, Switzerland, Altamira Therapeutics is committed to transforming RNA delivery systems. The company continues to seek licensing opportunities to support its goals. With a focus on innovative solutions, Altamira is well-positioned to make a meaningful impact in the biotech sector.
Frequently Asked Questions
What is the H.C. Wainwright Conference?
The H.C. Wainwright Conference is an annual gathering that brings together prominent companies in the investment sector to showcase their innovations and connect with investors.
When will Altamira's presentation take place?
Altamira's presentation is set for September 9, 2024, at 7:00 AM ET.
What technologies is Altamira focused on?
Altamira Therapeutics specializes in peptide-based nanoparticle technologies aimed at improving RNA delivery to non-liver tissues.
What are AM-401 and AM-411?
AM-401 is designed to target KRAS-driven cancers, while AM-411 focuses on treating rheumatoid arthritis, both of which are currently in preclinical development.
How can I connect with Altamira Therapeutics?
To arrange a direct meeting with company representatives, it is advisable to reach out via email to their investor relations department.
